Efficacy and safety of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC): Results from a multicenter, single-arm, phase II study

被引：0
|
作者：
Xiong, Anwen
Li, XingYa
Yang, Nong
Meng, Xiangjiao
Yu, Qitao
Tan, Liping
Wang, Qiming
Wang, Yongsheng
Liu, Baogang
Luo, Hui
Wang, Ying
Huang, Dingzhi
Zhang, Yiping
Song, Zhengbo
Ye, Feng
Fang, Jian
Zhao, Mingfang
Wang, Yongsheng
Sun, Yinghui
Zhou, Caicun
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Canc Inst,Sch Med, Shanghai, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosp 1, Dept Med Oncol, Zhengzhou, Peoples R China
[3] Cent South Univ, Lung Canc & Gastrointestinal Unit, Dept Med Oncol,Xiangya Sch Med, Hunan Canc Hosp,Affiliated Canc Hosp, Changsha, Peoples R China
[4] Shandong Canc Hosp, Jinan, Peoples R China
[5] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Resp Oncol, Nanning, Peoples R China
[6] Zhengzhou Univ, Henan Canc Hosp, Dept Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[7] Sichuan Univ, West China Hosp, Clin Trial Ctr, Chengdu, Peoples R China
[8] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[9] Jiangxi Canc Hosp, Dept Thorac Tumor Radiotherapy Ward 2, Nanchang, Jiangxi, Peoples R China
[10] Chongqing Univ, Canc Hosp, Dept Radiat Oncol, Chongqing, Peoples R China
[11] Chongqing Canc Inst, Chongqing, Peoples R China
[12] Chongqing Canc Hosp, Chongqing, Peoples R China
[13] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Tianjin, Peoples R China
[14] Zhejiang Canc Hosp, Dept Thorac Oncol, Hangzhou, Peoples R China
[15] Xiamen Univ, Affiliated Hosp 1, Dept Med Oncol, Xiamen, Peoples R China
[16] Peking Univ Canc Hosp & Inst, Dept Thorac Oncol 2, Beijing, Peoples R China
[17] China Med Univ, Dept Med Oncol, Hosp 1, Shenyang, Peoples R China
[18] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Resp Med, Nanjing, Peoples R China
[19] Shouyao Holdings Beijing Co Ltd, Dept Clin Med, Beijing, Peoples R China
[20] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3106
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion plus non-small cell lung cancer (NSCLC).
    Gainor, Justin F.
    Lee, Dae Ho
    Curigliano, Giuseppe
    Doebele, Robert Charles
    Kim, Dong-Wan
    Baik, Christina S.
    Tan, Daniel Shao-Weng
    Lopes, Gilberto
    Gadgeel, Shirish M.
    Cassier, Philippe Alexandre
    Taylor, Matthew H.
    Liu, Stephen V.
    Besse, Benjamin
    Thomas, Michael
    Zhu, Viola Weijia
    Zhang, Hui
    Clifford, Corinne
    Palmer, Michael
    Turner, Christopher D.
    Subbiah, Vivek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors
    Zhou, Caicun
    Li, Wei
    Zhang, Yiping
    Song, Zhengbo
    Wang, Yongsheng
    Huang, Dingzhi
    Ye, Feng
    Wang, Qiming
    Sun, Yinghui
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer
    Zhou, Qing
    Zhao, Jun
    Chang, Jianhua
    Wang, Huijie
    Fan, Yun
    Wang, Ke
    Wu, Gang
    Nian, Weiqi
    Sun, Yuping
    Sun, Meili
    Wang, Xiangcai
    Shi, Huaqiu
    Zheng, Xiangqian
    Yao, Sheng
    Qin, Mengmeng
    Shen, Zhenwei
    Yang, Jason
    Wu, Yi-Long
    [J]. CANCER, 2023, 129 (20) : 3239 - 3251
  • [4] Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion plus Non-Small Cell Lung Cancer
    Zhou, Q.
    Wu, Y.
    Chang, J.
    Wang, H.
    Fan, Y.
    Zhao, J.
    Wu, G.
    Sun, Y.
    Sun, M.
    Wang, X.
    Shi, H.
    Nian, W.
    Wang, K.
    Zheng, X.
    Qu, L.
    Yao, S.
    Shen, Z.
    Li, P.
    Yang, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S889 - S890
  • [5] The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
    Ke, Jun-yi
    Huang, Shu
    Jing, Zhi-tao
    Duan, Min-chao
    [J]. INVESTIGATIONAL NEW DRUGS, 2023, 41 (05) : 768 - 776
  • [6] The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
    Jun-yi Ke
    Shu Huang
    Zhi-tao Jing
    Min-chao Duan
    [J]. Investigational New Drugs, 2023, 41 : 768 - 776
  • [7] Updated efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion plus non-small cell lung cancer
    Zhou, Q.
    Wu, Y-L.
    Zhao, J.
    Chang, J.
    Wang, H.
    Fan, Y.
    Wang, K.
    Wu, G.
    Nian, W.
    Gong, Y.
    Sun, Y.
    Sun, M.
    Wang, X.
    Shi, H.
    Zheng, X.
    Qin, M.
    Duan, X.
    Shen, Z.
    Yao, S.
    Yang, J.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1593 - S1593
  • [8] Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial
    Lu, S.
    Cheng, Y.
    Huang, D.
    Sun, Y.
    Wu, L.
    Zhou, C.
    Zhou, J.
    Guo, Y.
    Chen, L.
    Shao, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S888 - S889
  • [9] The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients
    Guowu Wu
    Longhua Guo
    Yinfang Gu
    Tanxiao Huang
    Ming Liu
    Xiaofang Zou
    Bo Yang
    Ping Huang
    Chunling Wen
    Lilan Yi
    Wenting Liao
    Dongdong Zhao
    Junlin Zhu
    Xiaoni Zhang
    Yuanyuan Liu
    Yan Yin
    Shifu Chen
    [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1019 - 1028
  • [10] The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients
    Wu, Guowu
    Guo, Longhua
    Gu, Yinfang
    Huang, Tanxiao
    Liu, Ming
    Zou, Xiaofang
    Yang, Bo
    Huang, Ping
    Wen, Chunling
    Yi, Lilan
    Liao, Wenting
    Zhao, Dongdong
    Zhu, Junlin
    Zhang, Xiaoni
    Liu, Yuanyuan
    Yin, Yan
    Chen, Shifu
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 1019 - 1028
12345